Systemic autoimmune diseases and work outcomes in Brazil: a scoping review

Autor(es)

Rafael Alves Cordeiro ^[1] ; Frida Marina Fischer ^[2] ; Samuel Katsuyuki Shinjo ^[3]

Afiliação do(s) autor(es)

^[1] Universidade de Sao Paulo. Faculdade de Medicina. Departamento de Reumatologia - Brasil

^[2] Universidade de Sao Paulo. Faculdade de Saude Publica. Departamento de Saude Ambiental - Brasil

^[3] Universidade de Sao Paulo. Faculdade de Medicina. Departamento de Reumatologia - Brasil

• Tipo de documento: Artigo Científico
• Fonte: Revista de Saúde Pública; v. 56, 2022-04-22.

Resumo

ABSTRACT OBJECTIVE To review articles that assessed work-related outcomes such as workability, work productivity, presenteeism, absenteeism, sick leave, return to work, and employment status of Brazilian patients with rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, Sjögren’s syndrome, and systemic autoimmune myopathies. METHODS This study was conducted in Medline databases (PubMed), SciELO, and Lilacs through a combination of descriptors of interest. Studies published until December 2020 were considered in the search strategy. RESULTS Eight out of 90 articles met the eligibility criteria and were included in this review. The studies are highly heterogeneous. Most of them are cross-sectional, and all of them address rheumatoid arthritis or systemic lupus erythematosus. A common denominator among these studies is the high proportion of patients outside the labor market. CONCLUSIONS In general, the studies show unfavorable labor outcomes and impaired participation in the Brazilian workforce among the samples of patients assessed. There is a need to better understand several topics about Brazilian patients with systemic autoimmune diseases and their work context, as well as to conduct studies focusing on rarer diseases and on the themes of return and reintegration to work. (AU)

• Processo FAPESP: 19/11776-6 - Impacto e segurança da neuromodulação cerebral não-invasiva em pacientes com doenças autoimunes sistêmicas: estudo duplo cego, randomizado e placebo-controlado
• Beneficiário: Samuel Katsuyuki Shinjo
• Modalidade de apoio: Auxílio à Pesquisa - Regular